Switzerland’s Roche has moved into pole position in the race to launch the world’s first treatment for progressive multiple sclerosis but smaller players are working hard on rival approaches.
While there are a number of treatments for relapsing remitting MS, the most common form of the disease, there are no approved drugs for progressive MS, which is marked by steadily worsening symptoms.
{iframe}http://health.economictimes.indiatimes.com/news/pharma/roche-gets-jump-on-rivals-in-race-for-progressive-ms-treatment/49152203{/iframe}